Tag: PAR

Paradigm Biopharma ASX PAR pain reduction treatment Pentosan Polysulfate Sodium

Paradigm Biopharma on track to deliver revolutionary pain reduction treatment

Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has added more patients to its trail of injectable Pentosan Polysulfate Sodium (PPS), whilst maintaining its 50% pain reduction rate. The...
Paradigm Biopharma ASX PAR osteoarthritis trial recruitment ahead of schedule

Paradigm Biopharma osteoarthritis trial recruitment ‘ahead of schedule’

Paradigm Biopharma (ASX: PAR) has recruited more than 80% of its patients needed for its phase 2b osteoarthritis and concurrent bone marrow lesion clinical...
Paradigm Biopharma ASX PAR AFL Penstosan Polysulfate Sodium osteoarthritis

AFL teams queue up for Paradigm Biopharma’s pain relieving medication

Several doctors from Australian Football League (AFL) clubs are taking advantage of Paradigm Biopharma’s (ASX: PAR) existing drug for the treatment for knee, hip...
Paradigm Biopharma ASX PAR clinical trail ross river virus Pentosan Polysulfate Sodium osteoarthritis

Paradigm Biopharma’s clinical trials in the fast lane

Paradigm Biopharmaceuticals (ASX: PAR) is surpassing its own expectations in recruiting patients for its two phase two clinical trials, which will speed up the...
Paradigm Biopharmaceuticals ASX PAR osteoarthritis pain Pentosan Polysulfate Sodium

Paradigm delivers positive trial results alongside growing patient numbers

Paradigm Biopharmaceuticals (ASX: PAR) has recorded pleasing trial results for its Pentosan Polysulfate Sodium (PPS) drug. In a statement to the market, Paradigm said that...
Paradigm Biopharma ASX PAR phase 2a clinical trial ACL injuries

Paradigm Biopharma unveils phase 2a clinical trial success for ACL injuries

Paradigm Biopharmaceuticals (ASX: PAR) announced a successful phase 2a clinic trial for treating bone marrow lesions with its pentosan polysulfate sodium drug (PPS) with...
Paradigm Biopharma reduce osteoarthritis pain Pentosan Polysulfate Sodium

Paradigm Biopharma reports success in reducing osteoarthritis pain

Paradigm Biopharmaceuticals (ASX: PAR) has reported an 83% pain reduction for osteoarthritis patients who were retreated with the company’s Pentosan Polysulfate Sodium (PPS). Current treatments...
Paradigm Biopharmaceutical ASX osteoarthritis pain Pentosan Polysulfate Sodium

Paradigm shift underway in treating osteoarthritis pain

Paradigm Biopharmaceuticals (ASX: PAR) has announced the peer-reviewed publication of a patient case study which confirms the significant potential of Pentosan Polysulfate Sodium (PPS)...
Paradigm Biopharma ASX PAR Phase 2 Ross River virus clinical trial

Paradigm Biopharma to commence Phase 2 Ross River virus trial

Paradigm Biopharmaceuticals (ASX: PAR) has initiated its two trial sites for its Phase 2 Alphavirus clinical trial of the drug Pentosan Polysulfate Sodium (PPS)...
Paradigm PAR ASX hay fever trial allergic rhinitis

Paradigm’s hay fever trial fails to meet endpoints

Paradigm Biopharmaceuticals (ASX: PAR) today announced that its Phase 2a allergic rhinitis (hay fever) clinical trial did not meet its primary endpoints (total nasal...
Paradigm Biopharma PAR allergic rhinitis hay fever

Paradigm Biopharma’s preclinical hay fever trial published in peer-reviewed scientific journal

Paradigm Biopharmaceuticals Ltd (ASX: PAR) announces the peer-reviewed publication validating the efficacy of PPS in experimental allergic rhinitis using an industry standard preclinical model. Key...